University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
NCT Number: NCT01756040
Necrotizing enterocolitis (NEC) is a life-threatening, gastrointestinal emergency characterized by increased intestinal permeability, affects approximately 7 to 10% of infants <1500 g birthweight, and typically occurs within 7 to 14 days of birth. Mortality is as high as 30-50%. Prematurity is the greatest risk factor for the development of NEC due to the physiological immaturity of the gastrointestinal tract and altered or abnormal gut microbiota. Several studies have demonstrated that the initiation of an intense systemic and local inflammatory cascade leads to intestinal necrosis. The human intestine is lined by a single layer of cells exquisitely responsive to multiple stimuli and is populated by a complex climax community of microbial partners. Under normal circumstances, these intestinal cells form a tight but selective barrier to "friends and foes": microbes and most environmental substances are held at bay, but nutrients are absorbed efficiently. Epithelial barrier integrity is itself dynamic and matures over time starting soon after birth, though the mechanisms regulating dynamic permeability are poorly understood. Low birth weight, prematurity, and early postnatal age are associated with a leaky gut. Although intestinal permeability is higher at birth in preterm than term infants, there is usually rapid maturation of the intestinal barrier over the first few days of life in both populations. The investigators hypothesize that increased levels of measures of intestinal permeability (urine lactulose/rhamnose (LA/Rh), and fecal alpha1- antitrypsin will identify infants at high risk for NEC and that intestinal probiotic strains will be associated with intestinal barrier maturation. The purpose of the study is to determine whether clinical factors in combination with non-invasive stool test such as antitrypsin (A1AT) and microbiota composition profile are associated with intestinal permeability determined by excretion of non-metabolized sugar probes in urine (LA/Rh ratio). These studies may lead to a non-invasive screening test to identify preterm infants at risk for NEC.
Looking for future studies?
Notify MeUp to 4 day
All sexes
Interventional
Phase 1
Baltimore, Maryland, 21201, United States
The proposed study will evaluate the intestinal permeability measured by the urinary La/Rh ratio at one timepoint between d7-10 of life in 200 preterm infants 24-32 weeks gestation in preparation for a future study of probiotics to improve intestinal permeability in this population.
Primary Objective: To estimate mean and variance in IP measured by urinary Lactulose/Rhamnose ratio at 7-10d of life in neonates born between 24 and 32 weeks of gestational age.
Secondary Objectives
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
Other names: dual sugar solution
Time frame: 7-10 days postnatal
Intestinal Permeability measured by urinary excretion of orally administered lactulose/rhamnose (La/Rh ratio)
Time frame: 7-10 days postnatal
Stool alpha-1 antitrypsin concentrations
Time frame: 7-10 days postnatal
Relative abundance (%) Clostridiales species
Time frame: 7-10 days postnatal
Number of days breast milk feeding prior to La/Rh measurement between d7-10 days of age.
Time frame: 0-28 days postnatal
Frequency of ≥ Stage 2 Necrotizing enterocolitis
Time frame: 7-10 days postnatal
Percent of participants with antibiotic exposure prior to La/Rh measurement
Time frame: 0-100 days postnatal
Postnatal age when all nutrition is provided by enteral feeds
University of Maryland, Baltimore
Other
Gut Permeability in Very Low Birth Weight Infants
Acronym: IPPI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07689669
Apnea, Apnea of Prematurity
Konya, Turkey (Türkiye)
View Trial DetailsNCT07622459
Female Urogenital Diseases and Pregnancy Complications, Mechanical Ventilation
Sanliurfa, Turkey (Türkiye)
View Trial DetailsNCT07577180
Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia (BPD)
Köseköy, Kocaeli, Turkey (Türkiye)
View Trial DetailsNCT07494123
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Cairo, Cairo Governorate, Egypt
View Trial Details